In a phase II trial in 87 previously treated KRAS mutant NSCLC patients the addition of the MEK1/2 inhibitor selumetinib to docetaxel improved ORR (37% vs. 0%, p < 0.0001) and median PFS (5.3 vs. 2.1 months, HR 0.58, p = 0.014) with a trend towards longer overall survival (9.4 vs. 5.2 months, HR 0.80, p = 0.21) [58]. The gene discussed is MAP2K1; the disease is non-small cell lung carcinoma.